Sensitivity, specificity, and stability of CSF-tau in AD in a community- based patient sample

Neurology

Volumn 53, Issue 7, 1999, Pages 1488-1494

  Andreasen, N ^a,g   Minthon, L ^b   Clarberg, A ^b   Davidsson, P ^c   Gottfries, J ^c   Vanmechelen, E ^d   Vanderstichele, H ^d   Winblad, B ^e   Blennow, K ^c,f  

^a River Valley Hospital   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d INNOGENETICS   (Belgium)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f Medical Research Council   (Sweden)

^g Pitea River Valley Hospital   (Sweden)

Author keywords

AD; Biochemical markers; CSF; Diagnosis; Progression; Tau protein

Indexed keywords

APOLIPOPROTEIN E; BIOCHEMICAL MARKER; TAU PROTEIN;

AGED; AGING; ALLELE; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC ACCURACY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0032693829     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.7.1488     Document Type: Article

References (37)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
2. Coleman PD, Flood DG. Neuron numbers and dendrite extent in normal aging and Alzheimer's disease. Neurobiol Aging 1987;8:521-545.
3. Blennow K, Bogdanovic N, Alafuzoff I, Ekman R, Davidsson P. Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J Neural Transm 1996;103:603-618.
4. Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci 1993;16:460-465.
5. Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993;61:1828-1834.
6. Arai H, Terajima M, Miura M, et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol 1995;38:649-652.
7. Blennow K, Wallin A, Ågren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer's disease? Mol Chem Neuropathol 1995;26:231-245.
8. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995;38:643-648.
9. Vigo-Pelfrey C, Seubert P, Barbour R, et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology 1995;45:788-793.
10. Tato RE, Frank A, Hernanz A. Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 1995;59:280-283.
11. Mori H, Hosoda K, Matsubara E, et al. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci Lett 1995;186: 181-183.
12. Nitsch RM, Rebeck GW, Deng M, et al. Cerebrospinal fluid levels of amyloid β-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype. Ann Neurol 1995;37:512-518.
13. Munroe WA, Southwick PC, Chang L, et al. Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. Ann Clin Lab Sci 1995;25:207-217.
14. Rösler N, Wichart I, Jellinger KA. Total tau protein immuno-reactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1996;60: 237-238.
15. Galasko D, Clark C, Chang L, et al. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology 1997;48:632-635.
16. Golombowski S, Muller-Spahn F, Romig H, Mendla K, Hock C. Dependence of cerebrospinal fluid tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease. Neurosci Lett 1997;225:213-215.
17. Andreasen N, Vanmechelen E, Van de Voorde A, et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry 1998;64:298-305.
18. Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998;55:937-945.
19. Andreasen N, Blennow K, Sjödin C, Winblad B, Svärsudd K. Prevalence and incidence of clinically diagnosed memory impairments in a geographically defined general population in Sweden: the Piteå Dementia Project. Neuroepidemiology 1999;18:144-155.
20. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed., revised. Washington, DC: American Psychiatric Association, 1987.
21. Folstein M, Folstein S, McHugh P. "Mini-mental state" - a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
22. Blennow K, Wallin A, Gottfries CG, et al. Cerebrospinal fluid monoamine metabolites in 114 healthy individuals 18-88 years of age. Eur Neuropsychopharmacol 1993;3:55-61.
23. Blennow K, Fredman P, Wallin A, et al. Protein analyses in cerebrospinal fluid: II. Reference values derived from healthy individuals 18-88 years of age. Eur Neurol 1993;33:129-133.
24. Tierney MC, Fisher RH, Lewis AJ, et al. The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathologic study of 57 cases. Neurology 1988;38:359-364.
25. Galasko D, Hansen LA, Katzman R, et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 1994;51:888-895.
26. Klatka LA, Schiffer RB, Powers JM, Kazee AM. Incorrect diagnosis of Alzheimer's disease. A clinicopathologic study. Arch Neurol 1997;53:35-42.
27. Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med 1998;338:506-511.
28. Galasko D. Cerebrospinal fluid levels of Aβb42 and tau: potential markers of Alzheimer's disease. J Neural Transm 1998; 53:209-221.
29. Blennow K, Vanmechelen E. Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing. J Neural Transm 1998;53:223-235.
30. Zapotoczky HG. Problems of differential diagnosis between depressive pseudodementia and Alzheimer's disease. In: Jellinger K, Fazekas F, Windisch M, eds. Ageing and dementia. New York: Springer Verlag, 1998:91-95.
31. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Consensus report of the Working Group on Molecular and Biochemical Markers of Alzheimer's Disease. Neurobiol Aging 1998;19:109-116.
32. Otto M, Wiltfang J, Tumani H, et al. Elevated levels of tauprotein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett 1997;225:210-212.
33. Molina JA, Benito-Leon J, Jimenez-Jimenez FJ, et al. Tau protein concentrations in cerebrospinal fluid of non-demented Parkinson's disease patients. Neurosci Lett 1997;238:139-141.
34. Tapiola T, Overmyer M, Lehtovirta M, et al. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease. Neuroreport 1997;8:3961-3963.
35. Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund LO. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up. Neurosci Lett 1996;214:163-166.
36. Butler SM, Ashford JW, Snowdon DA. Age, education, and changes in the Mini-Mental State Exam scores of older women: findings from the Nun Study. J Am Geriatr Soc 1996;44: 675-681.
37. Christensen H, Korten AE, Jorm AF, et al. Education and decline in cognitive performance: compensatory but not protective. Int J Geriatr Psychiatry 1997;12:323-330.